Spiriva leads charge for Boehringer

pharmafile | April 23, 2009 | News story | Sales and Marketing |  Boehringer, COPD 

Related Content

How will biomarker-led diagnostics reshape respiratory medicine?

By Dr Louise Ryan Murphy, Chronic obstructive pulmonary disease (COPD) is typically diagnosed and assessed …

Five Facts about COPD

1 Chronic obstructive pulmonary disease is a group of progressive lung conditions, principally emphysema and …

AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials

AstraZeneca’s tozorakimab reduced moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) in two …

The Gateway to Local Adoption Series

Latest content